The U.S. Food and Drug Administration (FDA) has recently approved Rocklatan™ (netarsudil and latanoprost ophthalmic solution), 0.02%/0.005% for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Reduction of IOP is currently the only modifiable risk factor to prevent or slow damage to the optic nerve in glaucoma. Rhopressa®, approved last year as a new treatment option, is a first-in-class Rho kinase (ROCK) inhibitor specifically designed to target the trabecular meshwork (the eye’s principal drainage pathway). It reduces IOP by restoring outflow through the trabecular meshwork. Latanaoprost is a commonly used medication to lower eye pressure that improves drainage through a pathway known as uveoscleral outflow.
